key: cord-0743416-0yr1rx71
authors: da Silva, D. L.; Ferreira Filho, A. F.; Van der Ham, R.; Scheffer, J. L.; Peixoto, J. L.
title: SIOG2021-0135 Impact of COVID-19 pandemic on early mortality of older patients with cancer in a Brazilian Oncology Unity
date: 2021-12-31
journal: Journal of Geriatric Oncology
DOI: 10.1016/s1879-4068(21)00480-x
sha: f8c77cf1d6c01f5cc8a14a9ca2915a556f0afbaf
doc_id: 743416
cord_uid: 0yr1rx71

nan

Introduction: The COVID-19 pandemic has worldwide disrupted cancer control since screening has been diminished or suspended, routine diagnostic work postponed, and emergency cases prioritized for diagnostic and therapeutic intervention. In Brazil, with already troublesome access to specialized cancer care to the Public health system (SUS), such disruptions may have placed the population of older patients with cancer (OPWC) in an especially dire situation. High 30-day mortality after first admission to oncology units (ambulatory or hospitalized patients), is an indicator of cancer clinical severity.

Objectives: To evaluate and compare early 30-day mortality of OPWC ≥ 65 years old on the period of pre-pandemia ( jan/2018feb/2020) and pandemia (march/2020 to march/2021) after first admission in our Oncology Unit.

Methods: The population of OPWC were analyzed regarding 30-day early mortality. The analysis were done in both the prepandemia and pandemia periods, as defined above. We subdivided the patients between those who were initially hospitalized or not and received or not chemotherapy. We also collected data regarding the time from diagnosis to time to access to specialized care on both periods.

Results and Conclusion: In the pre-pandemia period (25 months), there were 47 early deaths (1,6 patients per month), compared to 30 early deaths occurring in the pandemia period of 12 months (2,5 patients per month), a relative increase of 64%. The distribution of these deaths is as follows: 29 deaths of the prepandemia period (61%) occurred in hospitalized patients, compared to 20 deaths (66%) in the pandemia period. We observed low use of chemotherapy in the last 30 days of life of these patients (0,8% and 1,5%) for the pre and pandemia periods. In addition, medium time from cancer diagnosis to consultation in the public health system was 80 and 88 days in the pre-pandemic and pandemia period, respectively.

We hypothesize that the detected relative increase (64%) in the early mortality of OPWC during the COVID-19 pandemia was related to the increased gravity of patients arriving to initiate cancer treatment in our oncology unit. Possible contributing factors were delayed diagnosis, an increased time to consultation after diagnosis (a 10% relative increase in an already unacceptable delay on the pre-pandemic period), and more difficulty to access specialized care and specific anti-cancer therapies such as nonemergency surgeries. Journal of Geriatric Oncology 12 (8) (2021) S1-S78 S74

Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Imaging of prostate cancer local recurrences: why and how?

Salvage Radiotherapy for Prostate Cancer

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer

Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer